Gastrointestinal cancer. Over the RAINBOW--renaissance in antiangiogenesis.
The RAINBOW study has demonstrated that ramucirumab plus paclitaxel as second-line treatment for advanced-stage gastric cancer prolongs survival compared with paclitaxel alone. These data confirm that ramucirumab represents a new effective treatment option for gastric cancer. Nevertheless, new treatment options remain eagerly awaited in this disease with dismal outcomes.
University Cancer Centre Leipzig (UCCL), University Hospital Leipzig, Liebigstrasse 20, D-04103 Leipzig, Germany.
Florian
F
Lordick
D000230:Adenocarcinoma / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012074:Remission Induction / Q000379:methods*; D013274:Stomach Neoplasms / Q000188:drug therapy*